Screener
Summit Therapeutics SMMT Business Segments — Other expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Oncology clinical trial related costs | $90,195 | $36,363 |
| Compensation related costs, excluding stock-based compensation | 26,432 | 15,854 |
| Stock-based compensation | 72,791 | 11,096 |
| Other expenses (1) | 5,794 | 3,538 |
| Total segment expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's business segments — other expenses?
- Summit Therapeutics (SMMT) reported business segments — other expenses of $5.79M in Q1 2026.
- How has Summit Therapeutics's business segments — other expenses changed year-over-year?
- Summit Therapeutics's business segments — other expenses increased by 63.8% year-over-year, from $3.54M to $5.79M.
- What is the long-term trend for Summit Therapeutics's business segments — other expenses?
- Over 3 years (2022 to 2025), Summit Therapeutics's business segments — other expenses has grown at a -25.0% compound annual growth rate (CAGR), from $47.45M to $19.99M.
- What does business segments — other expenses mean?
- Captures miscellaneous operating costs not categorized under research, compensation, or major overhead line items. These are typically smaller, recurring operational costs necessary to support the segment's daily functions.
Ask your AI about Summit Therapeutics's business segments — other expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude